Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Basma Elhaddad

Alexandria University, Egypt

Title: Immunohistochemical study of the stem cell marker Foxl1 in bile ductular proliferation and liver cell regeneration in liver biopsies from infants with cholestasis

Biography

Biography: Basma Elhaddad

Abstract

Liver cell regeneration takes place through mature hepatocytes. However, in cases of chronic or severe injury, an alternative pathway takes place through the proliferation of hepatic progenitor cells (HPCs). The aim of the study was to investigate the distribution and number of Foxl1 positive HPCs in the livers of infants with different cholestatic diseases. Therefore, immunohistochemistry using Foxl1 antibody (ab190226) was conducted on fifty-three formalin fixed paraffin embedded blocks of liver biopsies from infants with neonatal cholestasis with the following diagnoses: Thirty cases of extrahepatic biliary atresia (EHBA), eleven cases of paucity of intrahepatic bile ducts (PIBD), eight cases of idiopathic neonatal giant cell hepatitis (NGCH) and four cases of galactosemia. Trichrome staining was done to asses the stage of fibrosis according to a previously published modified scoring system. Foxl1 Positive cells were seen in the periportal area and their numbers were much higher in liver biopsies obtained from infants with EHBA compared to the other diagnoses. Significant positive correlations were found between the number of HPCs and stage of fibrosis, the degree of ductular proliferation, the presence of portal tract neutrophils as well as higher levels of serum gamma-glutamyltransferase. In conclusion, HPCs are markedly activated in EHBA and their activation might be the reason for the associated ductular proliferation and fibrosis. However,  the type of inflammatory infiltrate might play a role in HPC activation as well. This may help to guide further research on animal models to design HPC-based antifibrotic therapies for cholestatic liver diseases.